Moderna Inc. has announced that the European Medicines Agency's $(EMA)$ Committee for Medicinal Products for Human Use $(CHMP)$ has adopted a positive opinion recommending marketing authorization for Moderna's updated COVID-19 mRNA vaccine. This updated vaccine targets the SARS-CoV-2 variant LP.8.1 and is intended for active immunization to prevent COVID-19 in individuals aged six months and older. The decision is a significant milestone as it marks progress in Moderna's efforts to protect populations across the European Union. The CHMP's decision is based on comprehensive data, including manufacturing, preclinical, and previous clinical evidence, as well as real-world efficacy and safety data. The updated vaccine's composition is consistent with guidance from global health authorities, identifying the LP.8.1 strain as suitable for the 2025-2026 vaccination season. The European Commission will now make a final marketing authorization decision.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.